|
?:authorAffiliation
|
-
[\'Deming Department of Medicine, Tulane University, New Orleans, Louisiana, USA pedrobaratamd@gmail.com.\', \'Department of Medical Oncology, University of Utah, Salt Lake City, Utah, USA.\', \'Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, USA.\', \'Deming Department of Medicine, Tulane University, New Orleans, Louisiana, USA.\', \'Department of Medicine, University of Arizona Arizona Cancer Center, Tucson, Arizona, USA.\', \'Department of Oncology, Mayo Clinic, Scottsdale, Arizona, USA.\', \'Division of Hematology, Oncology, and Blood and Marrow Transplant, University of Iowa, Iowa City, Iowa, USA.\', \'Genitourinary Oncology Program, Division of Hematology, Oncology and Blood and Marrow Transplantation, The University of Iowa, Iowa City, Iowa, USA.\', \'Guardant Health Inc, Redwood City, California, USA.\', \'Department of Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.\']
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}